Download this white paper to learn more.
Microbial-based fermentation can yield major benefits for patients and manufacturers. It allows for both faster processes and notable cost-savings; that said, it comes with inherent challenges and requires expert understanding and handling. Oftentimes, microbial-based products are unique, complex molecules that require specific processes that may not be platform-based. They require specific purification techniques and specialists that can think critically to adapt approaches.
In many cases, complex microbial-based biologics are born out of university offshoots and small biotech companies funded by private equity or venture capital firms who stage-gate funding. In such cases, reaching toxicology trials is a major step toward unlocking additional resources.
The key is working with a CDMO partner that has the knowledge and experience to navigate the inherent challenges of microbial fermentation and complex process development effectively and efficiently.
Download to learn more in this white paper from Steve Loftus, PhD, Commercial Technical Lead for Biologics, FUJIFILM Biotechnologies.
Offered Free by: FUJIFILM Biotechnologies
See All Resources from: FUJIFILM Biotechnologies
